Who are Paroxetine+Lamotrigine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paroxetine-lamotrigine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paroxetine+Lamotrigine — Competitive Intelligence Brief

Paroxetine+Lamotrigine (Paroxetine+Lamotrigine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI + anticonvulsant mood stabilizer combination. Area: Psychiatry / Neurology.

marketed SSRI + anticonvulsant mood stabilizer combination Serotonin transporter (SERT); voltage-gated sodium channels; glutamate release modulation Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Paroxetine+Lamotrigine (Paroxetine+Lamotrigine) — Ministry of Health & Welfare, Korea. This combination pairs a selective serotonin reuptake inhibitor (paroxetine) with an anticonvulsant mood stabilizer (lamotrigine) to enhance serotonergic neurotransmission while modulating glutamate and sodium channels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paroxetine+Lamotrigine TARGET	Paroxetine+Lamotrigine	Ministry of Health & Welfare, Korea	marketed	SSRI + anticonvulsant mood stabilizer combination	Serotonin transporter (SERT); voltage-gated sodium channels; glutamate release modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI + anticonvulsant mood stabilizer combination class)

Ministry of Health & Welfare, Korea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paroxetine+Lamotrigine — Competitive Intelligence Brief. https://druglandscape.com/ci/paroxetine-lamotrigine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab